• Home
  • Articles
  • Global News
  • Interest
  • Global Events
    • Add Event
  • Health Tips
  • Knowledge
    • Drug Directory
    • Education
      • Pharmacy Case Study
      • Pharmacy eBook Reviews
    • Pharma Companies
    • Dictionary Online
    • Career
    • Pharma Video
    • Featured Pharma Leader
  • About
    • Contact Us
    • Write for Us
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Email

Pharma Mirror Magazine

Mobile Logo

Browse Tag

GeneFusion Assay

Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla™ GeneFusion Assay
Pharmaceutical News

Biocartis Receives EUR 1.2 million Grant for Development of Highly Innovative Idylla™ GeneFusion Assay

October 1, 2020October 1, 2020

Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has

More

Subscribe

Subscribe our Articles, please enter your email below:

Please verify the email sent to your inbox to complete the subscription process. It's safe and free too.

Recent Posts

  • Using Behavioral Science in A Digital World October 22, 2020
  • CPhI Worldwide to return in 2021: Milan venue to play host to global pharma October 21, 2020
  • COVID-19 biologics will put huge pressure on large-scale bioprocessing networks October 21, 2020
  • Treatment for Histoplasmosis October 14, 2020
  • Romaco implements new sustainability strategy October 7, 2020

Event Partnership

Healthcare-Leaders-ANZ-FORUM-2020
PHARMA MIRROR partners with Purify 2020
  • Facebook
  • Twitter
  • LinkedIn
  • Email

© 2010-2020 PharmaMirror.com - All Rights Reserved.

  • Home
  • Articles
  • Global News
  • Interest
  • Global Events
    • Add Event
  • Health Tips
  • Knowledge
    • Drug Directory
    • Education
      • Pharmacy Case Study
      • Pharmacy eBook Reviews
    • Pharma Companies
    • Dictionary Online
    • Career
    • Pharma Video
    • Featured Pharma Leader
  • About
    • Contact Us
    • Write for Us
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Email
Go toTop